Should I Buy TEVA? TEVA 2026 Analysis

Should You Buy Teva Pharmaceutical Industries Ltd (TEVA) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Buy

Latest Price

30.120

1 Day change

6.24%

52 Week Range

37.340

Analysis Updated At

2026/03/27

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Teva Pharmaceutical Industries Ltd (TEVA) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock shows strong long-term growth potential, supported by positive analyst ratings, an improving business profile, and favorable trading signals. While short-term technical indicators are neutral, the SwingMax signal and analyst sentiment suggest an attractive entry point for long-term gains.

Technical Analysis

The MACD is slightly negative and contracting, indicating no strong momentum. RSI is neutral at 51.538, and moving averages are converging. The stock is trading near its pivot level of 29.342, with resistance at 30.152 and support at 28.532. Short-term technical indicators are neutral.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

The low put-call ratios suggest a bullish sentiment in the options market, with more interest in calls than puts.

Technical Summary

Sell

Buy

Positive Catalysts

SwingMax signal on 2026-03-19 indicates a buy opportunity with a 1.80% price increase since then.
Analysts have consistently raised price targets, with the highest at $45, citing strong R&D productivity, revenue growth, and margin expansion.
The company's biosimilars and neuroscience/immunology verticals are expected to drive long-term growth.
Gross margin increased by 10.54% YoY, reflecting operational efficiency.

Neutral/Negative Catalysts

Net income and EPS showed significant declines in 2025/Q4, with net income dropping by -321.20% YoY and EPS by -315.79% YoY.
No recent news or significant trading trends from hedge funds or insiders.

Financial Performance

In 2025/Q4, revenue increased by 12.61% YoY to $4.725 billion, and gross margin improved to 56.74%. However, net income dropped significantly by -321.20% YoY to $480 million, and EPS fell by -315.79% to 0.41, indicating challenges in profitability despite revenue growth.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analysts are highly positive on TEVA, with multiple firms raising price targets recently. The highest price target is $45, and the consensus is that the company's improved business profile, R&D productivity, and growth in key verticals justify further valuation expansion. Ratings are predominantly Buy or Overweight.

11 Analyst Rating

Wall Street analysts forecast TEVA stock price to rise

10 Buy

1 Hold

0 Sell

Strong Buy

Current: 28.350

Low

Averages

35.71

High

Current: 28.350

Low

Averages

35.71

High

Piper Sandler

David Amsellem

Overweight

maintain

$40 -> $41

AI Analysis

2026-03-04

Reason

Piper Sandler

David Amsellem

Price Target

$40 -> $41

AI Analysis

2026-03-04

maintain

Overweight

Reason

Piper Sandler analyst David Amsellem raised the firm's price target on Teva to $41 from $40 and keeps an Overweight rating on the shares after meeting with management. Key discussion topics included a number of bigger picture considerations, including management's approach to innovative R&D and its vision for the R&D organization; how the team is thinking about further build-out of its core neuroscience and immunology verticals; its vision for the biosimilars business; and the approach to capital deployment amid growth in cash generation. With an attractive long-term top-line/EBITDA growth story coming into focus, in the context of continued improvement in the capital structure and an absence of loss of exclusivity exposure, the firm would argue for further multiple expansion from a current EV/2026 EBITDA of 10 times.

BofA

Buy

maintain

$37 -> $38

2026-02-18

Reason

BofA

Price Target

$37 -> $38

2026-02-18

maintain

Buy

Reason

BofA raised the firm's price target on Teva (TEVA) to $38 from $37 and keeps a Buy rating on the shares after the company and partner Sanofi (SNY) announced Phase 2 maintenance data from the RELIEVE UCCD long-term extension study of duvakitug in inflammatory bowel diseases. Based on yesterday's update, the firm edged up its multiple, reflecting $1B in higher duvakitug peak sales, now seen at a $3B peak.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for TEVA

Unlock Now

TEVA Should I Buy

TEVA Should I Buy

Should You Buy Teva Pharmaceutical Industries Ltd (TEVA) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch